SNCE
Science 37 Holdings, Inc. [SNCE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SNCE Stock Summary
In the News
SNCE Financial details
Company Rating
Sell
Market Cap
34.66M
Income
-123.53M
Revenue
60.26M
Book val./share
0.44
Cash/share
0.48
Dividend
-
Dividend %
-
Employees
460
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-5.74
Forward P/E
-
PEG
0.57
P/S
0.59
P/B
13.7
P/C
11.98
P/FCF
-0.49
Quick Ratio
3.81
Current Ratio
4.17
Debt / Equity
0.01
LT Debt / Equity
0
-
-
EPS (TTM)
-1.06
EPS next Y
-
EPS next Q
-
EPS this Y
-99.98%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-3.02%
EPS Q/Q
-29.41%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-14.29%
Inst Own
17.52%
Inst Trans
0.43%
ROA
-163%
ROE
-171%
ROC
-0.51%
Gross Margin
30%
Oper. Margin
-49%
Profit Margin
-205%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.73-12.96
52W High
-52.08%
52W Low
+91.67%
RSI
59
Rel Volume
0.89
Avg Volume
54.56K
Volume
48.81K
Perf Week
0%
Perf Month
0.88%
Perf Quarter
-
Perf Half Y
-28.13%
-
-
-
-
Beta
0.565
-
-
Volatility
0%, 0.02%
Prev Close
0%
Price
5.75
Change
0%
SNCE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2020-06-30 | 2021-06-30 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 1.59 | 1.82K | 0.61 | |
| Net income per share | 0 | -2.18 | -2.89K | -0.44 | |
| Operating cash flow per share | 0 | -1.71 | -1.12K | -0.65 | |
| Free cash flow per share | 0 | -2.13 | -1.75K | -0.93 | |
| Cash per share | 0.05 | 2.18 | 6.57K | 0.93 | |
| Book value per share | 0.04 | -7.14 | 3.72K | 0.84 | |
| Tangible book value per share | 0.04 | -7.68 | 2.98K | 0.84 | |
| Share holders equity per share | 0.04 | -7.14 | 3.72K | 0.84 | |
| Interest debt per share | 0 | 0.17 | 74.73 | -0.91 | |
| Market cap | 110.4M | 2.97B | 8.15M | 962.23M | |
| Enterprise value | 110.37M | 2.94B | -205.13M | 855.47M | |
| P/E ratio | -110.4K | -91.87 | -0.09 | -18.87 | |
| Price to sales ratio | 0 | 125.46 | 0.14 | 13.72 | |
| POCF ratio | 0 | -116.73 | -0.22 | -12.75 | |
| PFCF ratio | 0 | -93.98 | -0.14 | -8.97 | |
| P/B Ratio | 4.6K | -28.02 | 0.07 | 9.88 | |
| PTB ratio | 4.6K | -28.02 | 0.07 | 9.88 | |
| EV to sales | 0 | 124.19 | -3.44 | 12.2 | |
| Enterprise value over EBITDA | 0 | -111.21 | 8.33 | -6.14 | |
| EV to operating cash flow | 0 | -115.55 | 5.62 | -11.34 | |
| EV to free cash flow | 0 | -93.04 | 3.6 | -7.97 | |
| Earnings yield | 0 | -0.01 | -11.57 | -0.05 | |
| Free cash flow yield | 0 | -0.01 | -7 | -0.11 | |
| Debt to equity | 0 | -0.02 | 0.02 | 0.01 | |
| Debt to assets | 0 | 0.04 | 0.01 | 0.01 | |
| Net debt to EBITDA | 0 | 1.13 | 8.66 | 0.77 | |
| Current ratio | 0.86 | 2.52 | 6.64 | 5.45 | |
| Interest coverage | 0 | 0 | 0 | 0.99 | |
| Income quality | 0 | 0.8 | 0.39 | 1.48 | |
| Dividend Yield | 0 | 0.03 | 0 | 0 | |
| Payout ratio | 0 | -2.42 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0.02 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0.14 | 0.09 | 0 | |
| Capex to operating cash flow | 0 | 0.24 | 0.56 | 0.42 | |
| Capex to revenue | 0 | -0.26 | -0.35 | -0.45 | |
| Capex to depreciation | 0 | -1.39 | -2.64 | -1.78 | |
| Stock based compensation to revenue | 0 | 0.01 | 0.14 | 0.35 | |
| Graham number | 0.04 | 18.7 | 15.55K | 2.88 | |
| ROIC | 0 | 0.32 | -0.51 | -1.06 | |
| Return on tangible assets | -0.02 | -0.66 | -0.4 | -0.4 | |
| Graham Net | -0.01 | -8.15 | 2.55K | 0.75 | |
| Working capital | -4K | 27.75M | 197.68M | 103.03M | |
| Tangible asset value | 24K | -114.19M | 97.31M | 97.39M | |
| Net current asset value | -4K | -117.12M | 93.5M | 97.14M | |
| Invested capital | 0 | -0.02 | 0.02 | 0.01 | |
| Average receivables | 0 | 5.6M | 10.95M | 10.85M | |
| Average payables | 0 | 2.2M | 8.61M | 10.01M | |
| Average inventory | 0 | 1.14M | 1.14M | 0 | |
| Days sales outstanding | 0 | 172.46 | 65.53 | 57.2 | |
| Days payables outstanding | 0 | 71.1 | 110.37 | 48.46 | |
| Days of inventory on hand | 0 | 36.97 | 0 | 0 | |
| Receivables turnover | 0 | 2.12 | 5.57 | 6.38 | |
| Payables turnover | 0 | 5.13 | 3.31 | 7.53 | |
| Inventory turnover | 0 | 9.87 | 0 | 0 | |
| ROE | -0.04 | 0.3 | -0.78 | -0.52 | |
| Capex per share | 0 | -0.41 | -629.64 | -0.28 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.14 | 0.14 | 0.12 | 0.13 | 0.13 | |
| Net income per share | -0.17 | -0.57 | -0.2 | -0.17 | -0.12 | |
| Operating cash flow per share | -0.09 | -0.13 | -0.17 | -0.11 | 0 | |
| Free cash flow per share | -0.16 | -0.19 | -0.22 | -0.15 | -0.07 | |
| Cash per share | 1.12 | 0.93 | 0.71 | 0.56 | 0.48 | |
| Book value per share | 1.36 | 0.84 | 0.67 | 0.53 | 0.44 | |
| Tangible book value per share | 1.01 | 0.84 | 0.67 | 0.53 | 0.44 | |
| Share holders equity per share | 1.36 | 0.84 | 0.67 | 0.53 | 0.44 | |
| Interest debt per share | 0.02 | 0.78 | 0 | 0.01 | 0 | |
| Market cap | 3.75B | 966.57M | 655.85M | 496.91M | 945.17M | |
| Enterprise value | 3.62B | 859.8M | 574.38M | 432.93M | 889.34M | |
| P/E ratio | -46.78 | -3.63 | -6.97 | -6.34 | -16.97 | |
| Price to sales ratio | 230.69 | 60.65 | 46.56 | 32.37 | 63.49 | |
| POCF ratio | -373.99 | -64.16 | -33.44 | -37.89 | -2.36K | |
| PFCF ratio | -203.44 | -43.64 | -25.66 | -28.14 | -113.48 | |
| P/B Ratio | 23.63 | 9.93 | 8.4 | 7.98 | 18.27 | |
| PTB ratio | 23.63 | 9.93 | 8.4 | 7.98 | 18.27 | |
| EV to sales | 222.77 | 53.95 | 40.78 | 28.2 | 59.74 | |
| Enterprise value over EBITDA | -167.63 | 29.87 | -59.93 | -201.08 | -271.8 | |
| EV to operating cash flow | -361.14 | -57.07 | -29.29 | -33.01 | -2.22K | |
| EV to free cash flow | -196.46 | -38.82 | -22.47 | -24.52 | -106.78 | |
| Earnings yield | -0.01 | -0.07 | -0.04 | -0.04 | -0.01 | |
| Free cash flow yield | 0 | -0.02 | -0.04 | -0.04 | -0.01 | |
| Debt to equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | |
| Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | 5.96 | -3.71 | 8.5 | 29.71 | 17.06 | |
| Current ratio | 6.32 | 5.45 | 5.85 | 4.62 | 4.17 | |
| Interest coverage | -45.19 | 0.26 | 15.82 | 0 | 0 | |
| Income quality | 0.43 | 0.23 | 0.8 | 0.67 | 0.03 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.22 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.84 | 0.47 | 0.3 | 0.35 | 19.82 | |
| Capex to revenue | -0.52 | -0.44 | -0.42 | -0.3 | -0.53 | |
| Capex to depreciation | -1.73 | -1.32 | -27.92 | -31.56 | -48.64 | |
| Stock based compensation to revenue | 0.35 | 0.32 | 0.36 | 0.23 | 0.24 | |
| Graham number | 2.3 | 3.28 | 1.75 | 1.42 | 1.08 | |
| ROIC | -0.13 | 0.24 | -0.21 | -0.45 | -0.27 | |
| Return on tangible assets | -0.14 | -0.53 | -0.23 | -0.23 | -0.18 | |
| Graham Net | 0.91 | 0.75 | 0.61 | 0.47 | 0.38 | |
| Working capital | 122.83M | 103.03M | 83.94M | 67.96M | 57.44M | |
| Tangible asset value | 117.55M | 97.39M | 78.11M | 62.25M | 51.74M | |
| Net current asset value | 115.1M | 97.14M | 77.91M | 62.05M | 51.56M | |
| Invested capital | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | |
| Average receivables | 11.1M | 10.01M | 11.34M | 13.26M | 13.71M | |
| Average payables | 7.92M | 6.91M | 6.47M | 5.84M | 6.31M | |
| Average inventory | 0 | 0 | 3.35M | 6.65M | 6.38M | |
| Days sales outstanding | 49.95 | 62.08 | 74.62 | 86.96 | 76.12 | |
| Days payables outstanding | 48.92 | 52.76 | 46.39 | 53.79 | 66.86 | |
| Days of inventory on hand | 0 | 0 | 54.32 | 59.53 | 61.92 | |
| Receivables turnover | 1.8 | 1.45 | 1.21 | 1.03 | 1.18 | |
| Payables turnover | 1.84 | 1.71 | 1.94 | 1.67 | 1.35 | |
| Inventory turnover | 0 | 0 | 1.66 | 1.51 | 1.45 | |
| ROE | -0.13 | -0.68 | -0.3 | -0.31 | -0.27 | |
| Capex per share | -0.07 | -0.06 | -0.05 | -0.04 | -0.07 |
SNCE Frequently Asked Questions
What is Science 37 Holdings, Inc. stock symbol ?
Science 37 Holdings, Inc. is a US stock , located in Research triangle park of Nc and trading under the symbol SNCE
What is Science 37 Holdings, Inc. stock quote today ?
Science 37 Holdings, Inc. stock price is $5.75 today.
Is Science 37 Holdings, Inc. stock public?
Yes, Science 37 Holdings, Inc. is a publicly traded company.
Company Profile
- Volume Average 54.56K
- Market Capitalization 34.66M
- Employee 460
- CEO Mr. David Coman
- Headquarters Research Triangle Park,NC,US
- IPO Date 2020-11-23
-
Website
https://www.science37.com 
Science 37 Holdings, Inc. provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data. Its platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating agile clinical trials; and extensive configuration to support virtually any phase of clinical study and any indication. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.
